NCT07400536

A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT

A Phase III, Multicenter, Open-label, Randomized Controlled Clinical Study on the Treatment of Locally Advanced Cervical Cancer With Cadonilimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 378 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study mainly evaluated the efficacy and safety of Cadonilimab combined with chemotherapy followed by concurrent chemoradiotherapy versus standard concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer.

Conditions

• Locally Advanced Cervical Carcinoma

Interventions

Type	Name	Description
RADIATION	standard EBRT+Brachytherapy	EBRT: 45-50.4Gy, Brachytherapy: 7Gy×4 or 6Gy ×5
DRUG	Concurrent chemotherapy	Cisplatin 40mg/m2, qw×5
DRUG	Immune induction therapy	Cadonilimab 10mg/kg q3w×2 + albumin paclitaxel 90mg/m2, qw×6+ cisplatin 25mg/m2, qw×6
RADIATION	Reduced dose radiotherapy	EBRT: 45-50.4Gy; Brachytherapy: 6Gy×4
DRUG	Dose reduction concurrent chemotherapy	cisplatin 25mg/m2, qw×5
DRUG	Immunomaintenance therapy	Cadonilimab 10mg/kg q3w×9 or half a year

Timeline

• Start date: 2026-03-30
• Primary completion: 2028-07-18
• Completion: 2032-07-20
• First posted: 2026-02-10
• Last updated: 2026-02-10